General Info

Founded in 1997 by Columbia University health professionals, scientists and engineers to improve the quality of life for the End Stage Renal Disease patient, Nephros has created one of the most effective ESRD therapies available worldwide. The company s development, Mid-Dilution Hemodiafiltration, is a unique and proprietary fluid management system offering optimized removal of renal toxins across the molecular spectrum. In concert with this technology, Nephros has developed a cost-effective online substitution fluid system that delivers ultra-pure substitution fluid in real-time. The company s Mid-Dilution Hemodiafiltration product also removes a range of harmful substances not currently removed by existing dialysis methods, as well as substances collectively known as middle molecules that contribute to such conditions as carpal tunnel syndrome, dialysis related amyloidosis and degenerative bone disease in the ESRD patient. Nephros maintains its headquarters in New York, as well as operating distribution centers in Italy, Germany, The Netherlands and Greece.